Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy

Neurological Research

Volumn 32, Issue 7, 2010, Pages 690-694

  Li, Shouwei ^a,b   Zhang, Wei ^a   Chen, Baoshi ^a   Jiang, Tao ^a,b   Wang, Zhongcheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma multiform; P53; prognosis; temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ABSENCE OF SIDE EFFECTS; ADULT; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77955628997     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164109X12478302362536     Document Type: Review

References (45)

1. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist 1999; 4: 209-224
2. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol 2002; 64: 259-273
3. Grossman SA, ONeill A, Grunnet M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003; 21: 1485-1491
4. Medical Research Council. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 2001; 19: 509-518
5. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-1329
6. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597
7. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018
8. Wolff JE, Berrak S, KoontzWebb SE, et al. Nitrosourea efficacy in high-grade glioma: A survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 2008; 88: 57-63
9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
10. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006; 24: 2563-2569
11. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005; 11: 6767-6771
12. Henson JW. Treatment of glioblastoma multiforme: A new standard. Arch Neurol 2006; 63: 337-341
13. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165-180
14. Hansen RJ, Nagasubramanian R, Delaney SM, et al. Role of O6- alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2- chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther 2005; 315: 1247-1255
15. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003
16. Pegg AE. Properties of mammalian O6-alkylguanine-DNA transferases. Mutat Res 1990; 233: 165-175
17. Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6- methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study. J Clin Oncol 2006; 24: 4746-4753
18. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomidemediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 2006; 12: 4738-4746
19. Fruehauf JP, Brem H, Brem S, et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 2006; 12: 4523-4532
20. Pollack IF, Hamilton RL, Sobol RW, et al. O6-methylguanine- DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 Cohort. J Clin Oncol 2006; 24: 3431-3437
21. Gilbert MR, Armstrong TS. Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide. Ther Clin Risk Manag 2007; 3: 1027-1033
22. Nagane M, Kobayashi K, Ohnishi A, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 2007; 37: 897-906
23. Ma J, Murphy M, ODwyer PJ, et al. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 2002; 63: 1219-1228
24. Nutt CL, Noble M, Chambers AF, et al. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res 2000; 60: 4812-4818
25. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005; 23: 7178-7187
26. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 1999; 96: 10764-10769
27. Stewart ZA, Pietenpol JA. p53 Signaling and cell cycle checkpoints. Chem Res Toxicol 2001; 14: 243-263
28. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310
29. Kleihues P, Cavenee WK. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System, Lyon: IARC Press, 2000
30. Macdonald DR, Cascino TL, Schold SC, Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280
31. Mrugala MM, Chamberlain MC. Mechanisms of disease: Temozolomide and glioblastoma-look to the future. Nat Clin Pract Oncol 2008; 5: 476-486
32. Xu GW, Mymryk JS, Cairncross JG. Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. Int J Cancer 2005; 116: 187-192
33. Batista LF, Roos WP, Christmann M, et al. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67: 11886-11895
34. Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006; 96: 766-776
35. Bocangel DB, Finkelstein S, Schold SC, et al. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002; 8: 2725-2734
36. Donato V, Papaleo A, Castrichino A, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 2007; 93: 248-256
37. Ribeiro Mde C, Coutinho LM, Hilbig A. The role of apoptosis, cell proliferation index, bcl-2, and p53 in glioblastoma prognosis. Arq Neuropsiquiatr 2004; 62: 262-270
38. Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002; 95: 249-257
39. Nieder C, Petersen S, Petersen C, et al. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 2000; 26: 67-73
40. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61: 1122-1128
41. Ganigi PM, Santosh V, Anandh B, et al. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005; 41: 292-299
42. Li SW, Jiang T, Li GL, et al. Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: Preliminary results. Neurol Res 2008; 30: 567-570
43. Yaman E, Buyukberber S, Uner A, et al. Temozolomide in newly diagnosed malignant gliomas: Administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Onkologie 2008; 31: 309-313 (Pubitemid 351839730)
44. Mineo JF, Bordron A, Baroncini M, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: A multivariate analysis of 340 patients. Acta Neurochir (Wien) 2007; 149: 245-252
45. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/ CE.3. Lancet Oncol 2008; 9: 29-38